← All trials
NCT04542499
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2020
- Primary completion
- Jun 11, 2022
- Completion date
- Aug 11, 2022
- First posted
- Sep 9, 2020
- Last posted
- Dec 14, 2020
- Enrollment
- 368
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cerevel Therapeutics, LLCLead sponsor
- Cerevel Therapeutics, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.